About Stingray Therapeutics
Stingray Therapeutics is a private company based in Dallas, Texas. It has reported $8,584,110 raised in four offerings on Form D since August 2020. Its chief executive is Jonathan Northrup.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 1, 2024 | May 14, 2024 | $25,000of $5.0M target | 1 | $25,000 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 19, 2023 | Feb 2, 2024 | $436,758of $450K target | 21 | $20,798 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 23, 2023 | Mar 31, 2023amended Dec 28, 2023 | $6,612,080of $6.6M target | 52 | $127K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 31, 2020 | Aug 13, 2020amended May 26, 2021 | $1,510,272of $3.0M target | 9 | $167K | Debt, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
| Total, four offerings | $8,584,110 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Stingray Therapeutics's Form D filed May 14, 2024.
JN
Jonathan Northrup
Chief Executive Officer and director
SS
Sunil Sharma
Executive officer and director
UB
Uma Bhatt
Executive officer and director
Earlier filings also listed Scott Jordan (cio & treasurer, director, last listed May 2021).